Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 730357 long-term extension in moderate-to-severe plaque psoriasis
2018-003487-31Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevurogant in plaque psoriasis, sponsored by Boehringer Ingelheim. Primary endpoint: Exposure-adjusted rate of patients reporting a treatment-emergent adverse event. Started May 2019; status: terminated.
02
Drugs
bevurogant
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2018-003487-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003487-31.